Momentum has been building for Novartis, with the share price return up 16.9% year-to-date and a total return of 9.3% over the past year. This reflects renewed optimism around the company\u2019s growth prospects as well as its consistent long-term shareholder performance.<\/p>\n
Curious about what other pharma leaders are doing? Discover more in our comprehensive pharmaceutical stocks screener: See the full list for free.<\/a><\/p>\n With a recent run-up in the share price along with sustained growth in revenue and earnings, the key question for investors now is whether Novartis remains undervalued or if the market has already priced in its future growth potential.<\/p>\n Novartis\u2019 most-followed valuation narrative places fair value at CHF98.60, which is about 5.6% below the recent close of CHF104.08. This suggests the stock may be trading above what is justified by expected growth and profits.<\/p>\n Operational efficiency gains from portfolio streamlining (for example, previous spin-offs and exiting non-core lines) and productivity improvements are driving core margin expansion and higher free cash flow. These gains can be reinvested in research and development and shareholder returns, supporting long-term earnings and net margin growth.<\/p>\n Read the complete narrative.<\/a><\/p>\n Curious what specific profit targets\u2014and bold margin moves\u2014are backing this valuation call? The most popular narrative is betting on strong improvements ahead, setting a stage for figures that might surprise even seasoned investors. Click through and see what\u2019s driving analysts\u2019 fair value math.<\/p>\n Result: Fair Value of $98.60 (OVERVALUED)<\/p>\n Have a read of the narrative in full and understand what’s behind the forecasts.<\/a><\/p>\n However, pivotal risks remain. These include the threat of generic competition for key drugs and mounting global pricing pressures, both of which could quickly dampen growth expectations.<\/p>\n Find out about the key risks to this Novartis narrative.<\/a><\/p>\n Looking at Novartis through the lens of its price-to-earnings ratio, the story shifts. The company trades at 18.6x, lower than the European industry average of 22.9x and well below peers at 74.7x, and even beneath the fair ratio of 29.3x. This sizable gap hints at a possible value opportunity. Is the market missing something, or is caution warranted?<\/p>\n See what the numbers say about this price \u2014 find out in our valuation breakdown.<\/a><\/p>\n If you want to take your own approach or dig deeper into the numbers, shaping your own story is quick and easy. You can create a custom narrative in under three minutes. Do it your way<\/a><\/p>\n A great starting point for your Novartis research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.<\/p>\n Smart investors never settle for just one opportunity. Give yourself the edge by finding bold new angles and untapped markets right now with the Simply Wall Street Screener.<\/p>\n This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n Companies discussed in this article include NOVN.SW<\/a>.<\/p>\n Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Novartis (SWX:NOVN) shares have shown steady upward momentum over the past month, gaining 6%, and climbing 12% across…\n","protected":false},"author":2,"featured_media":18088,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[2125,1104,206],"class_list":{"0":"post-44830","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-earnings-growth","9":"tag-fair-value","10":"tag-novartis"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116356900768396303","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/44830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=44830"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/44830\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/18088"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=44830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=44830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=44830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}<\/a> SWX:NOVN PE Ratio as at Oct 2025 <\/p>\n